Platelet function and antiplatelet therapy in cardiovascular disease: Implications of genetic polymorphisms

Current Vascular Pharmacology

Volumn 9, Issue 4, 2011, Pages 479-489

  Shanker, Jayashree ^a   Gasparyan, Armen Yuri ^b   Kitas, George D ^b   Kakkar, Vijay V ^a,c  

^a THROMBOSIS RESEARCH INSTITUTE   (India)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

^c THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Antiplatelets; Atherosclerosis; Genetic polymorphism; Glycoprotein receptors; Inflammation; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CANGRELOR; CD40 LIGAND; CLOPIDOGREL; CYCLOOXYGENASE 1; CYTOCHROME P450 2C19; ELINOGREL; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRONECTIN; GLYCOPROTEIN; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IB IX IV; GLYCOPROTEIN IIIA; GLYCOPROTEIN VI; METOPROLOL; PADGEM PROTEIN; PRASUGREL; PROSTAGLANDIN SYNTHASE; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; THROMBIN RECEPTOR; THROMBOCYTE ANTIGEN; THROMBOXANE A2 RECEPTOR; TICAGRELOR; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; VERY LATE ACTIVATION ANTIGEN 2; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGE; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ATHEROTHROMBOSIS; BIOASSAY; BLEEDING; BODY MASS; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CELL STRUCTURE; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DEGRANULATION; DIABETES MELLITUS; DRUG DOSE ESCALATION; DRUG MEGADOSE; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENOTYPE; GOLD STANDARD; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOADING DRUG DOSE; LOSS OF FUNCTION MUTATION; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MULTICENTER STUDY (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGOMETRY; PROGNOSIS; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; SUDDEN DEATH; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; THROMBOGENESIS; THROMBOSIS;

ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 79959978247     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111796197224     Document Type: Article

References (129)

1. Smyth SS, McEver RP, Weyrich AS, et al.; 2009 Platelet Colloquium Participants. Platelet functions beyond hemostasis. J Thromb Haemost 2009; 7: 1759-66.
2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
3. Antoniades C, Bakogiannis C, Tousoulis D, Demosthenous M, Marinou K, Stefanadis C. Platelet activation in atherogenesis associated with low-grade inflammation. Inflamm Allergy Drug Targets 2010; 9: 334-45.
4. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2011; 31: 153-64.
5. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 2010; 8: 437-49.
6. O'Donnell CJ, Larson MG, Feng D, et al.; Framingham Heart Study. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001; 103: 3051-6.
7. Jagroop IA, Clatworthy I, Lewin J, Mikhailidis DP. Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets 2000; 11: 28-32.
8. Schäfer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 2008; 6: 52-60.
9. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
10. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost 2003; 9: 177-90.
11. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004; 114: 447-53.
12. Bombeli T, Schwartz BR, Harlan JM. Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha. J Exp Med 1998; 187: 329-39.
13. Goto S. Understanding the mechanism of platelet thrombus formation under blood flow conditions and the effect of new antiplatelet agents. Curr Vasc Pharmacol 2004; 2: 23-32.
14. Slotta JE, Braun OO, Menger MD, Thorlacius H. Capture of platelets to the endothelium of the femoral vein is mediated by CD62P and CD162. Platelets 2009; 20: 505-12.
15. Woollard KJ, Chin-Dusting J. Therapeutic targeting of p-selectin in atherosclerosis. Inflamm Allergy Drug Targets 2007; 6: 69-74.
16. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54: 669-77.
17. Choi WS, Jeon OH, Kim DS. CD40 ligand shedding is regulated by interaction of MMP-2 and platelet integrin alphaIIbbeta3. J Thromb Haemost 2010; 8: 1364-71.
18. Ferroni P, Basili S, Davi G. Platelet activation, inflammatory mediators and hypercholesterolemia. Curr Vasc Pharmacol 2003; 1: 157-69.
19. Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 2009; 21: 293-300.
20. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009; 102: 248-57.
21. Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 2010; 103: 71-82.
22. Kumbhani DJ, Bhatt DL. Use of oral antiplatelet agents in acute coronary syndromes. Arch Med Sci 2010; 6(1A): S48-S54.
23. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-8.
24. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-43.
25. Bonvini RF, Reny JL, Mach F, Zeller T, Fontana P. Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and clopidogrel resistance. Curr Vasc Pharmacol 2009; 7: 198-208.
26. Keller TT, Squizzato A, Middeldorp S. Clopidogrel plus aspirin vs. aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev 2007; (3): CD005158.
27. Berger JS, Bhatt DL, Cannon CP, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol 2009; 54: 1935-45.
28. Berger PB, Bhatt DL, Fuster V, et al.; CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010; 121: 2575-83.
29. Campbell-Scherer DL, Green LA. ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction. Am Fam Physician 2009; 79: 1080-6.
30. Cohen M. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Catheter Cardiovasc Interv 2009; 74: 579-97.
31. Savi P, Nurden P, Nurden AT, Levy-Toledano S, Herbert JM. Clopidogrel: a review of its mechanism of action. Platelets 1998; 9: 251-5.
32. Sharma RK, Reddy HK, Singh VN, Sharma R, Voelker DJ, Bhatt G. Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag 2009; 5: 965-72.
33. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
34. 12 receptor antagonists: role in coronary artery disease. Curr Vasc Pharmacol 2010; 8: 93-101.
35. Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009; 30: 1964-77.
36. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-60.
37. Norgard NB, Abu-Fadel M. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manag 2009; 5: 873-82.
38. Vivekananthan DP, Moliterno DJ. Glycoprotein IIb/IIIa combination therapy in acute myocardial infarction: tailoring therapies to optimize outcome. J Thromb Thrombolysis 2002; 13: 35-9.
39. Christiaens L, Macchi L. Monitoring of the antiplatelet drugs effect in patients with coronary artery disease: what is the real clinical impact? Curr Vasc Pharmacol 2007; 5: 293-301.
40. Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007; 120: 323-36.
41. Pedersen SB, Grove EL, Nielsen HL, Mortensen J, Kristensen SD, Hvas AM. Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry. Platelets 2009; 20: 415-20.
42. McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009; 35: 168-80.
43. Nielsen HL, Kristensen SD, Thygesen SS, et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res 2008; 123: 267-73.
44. van Werkum JW, Harmsze AM, Elsenberg EH, Bouman HJ, ten Berg JM, Hackeng CM. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 2008; 19: 479-88.
45. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34: 709-33.
46. Gasparyan AY. Aspirin resistance: More emphasis on definition and appropriate use of platelet function tests is needed. Arch Med Sci 2009; 5: 539-41.
47. Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29: 2877-85.
48. Paniccia R, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in highrisk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-47.
49. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-11.
50. Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010; 8: 351-9.
51. Cuisset T, Frere C, Poyet R, et al. Clopidogrel response: head-tohead comparison of different platelet assays to identify clopidogrel non-responder patients after coronary stenting. Arch Cardiovasc Dis 2010; 103: 39-45.
52. Gasparyan AY. Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc Health Risk Manag 2010; 6: 109-12.
53. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
54. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. Lancet 1997; 349: 385-8.
55. Kastrati A, Koch W, Gawaz M, et al. PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. J Am Coll Cardiol 2000; 36: 84-9.
56. Wiwanitkit V. PIA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIIa and its correlation with myocardial infarction: an appraisal. Clin Appl Thromb Hemost 2006; 12: 93-5.
57. Le Hello C, Morello R, Lequerrec A, Duarte C, Riddell J, Hamon M. Effect of PlA1/A2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stenting. Thromb J 2007; 5: 19.
58. Harris K, Nguyen P, Van Cott EM. Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. Am J Clin Pathol 2008; 129: 282-6.
59. Di Castelnuovo A, de Gaetano G, Benedetta Donati M, Iacoviello L. Platelet glycoprotein IIb/IIIa polymorphism and coronary artery disease: implications for clinical practice. Am J Pharmacogenomics 2005; 5: 93-9.
60. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 2004; 15: 89-93.
61. Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC. Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. Am Heart J 2002; 143: 76-82.
62. Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2002; 14: 51-8.
63. Papp E, Havasi V, Bene J, et al. Does glycoprotein IIIa gene (Pl(A) polymorphism influence clopidogrel resistance? a study in older patients. Drugs Aging 2007; 24: 345-50.
64. Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42: 1115-9.
65. Abderrazek F, Chakroun T, Addad F, et al. The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thromb Res 2010; 125: e265-8.
66. Cooke GE, Liu-Stratton Y, Ferketich AK, et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 2006; 47: 541-6.
67. Papp E, Havasi V, Bene J, et al. Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation? Ann Pharmacother 2005; 39: 1013-8.
68. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008; 66: 222-32.
69. Böttiger C, Kastrati A, Koch W, et al. Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement. Am J Cardiol 1999; 84: 987-91.
70. Lekakis J, Bisti S, Tsougos E, et al. Platelet glycoprotein IIb HPA-3 polymorphism and acute coronary syndromes. Int J Cardiol 2008; 127: 46-50.
71. Park S, Park HY, Park C, et al. Association of the gene polymorphisms of platelet glycoprotein Ia and IIb/IIIa with myocardial infarction and extent of coronary artery disease in the Korean population. Yonsei Med J 2004; 45: 428-34.
72. Surin WR, Barthwal MK, Dikshit M. Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis. Thromb Res 2008; 122: 786-803.
73. Clemetson KJ, Clemetson JM. Collagen receptors as potential targets for novel anti-platelet agents. Curr Pharm Des 2007; 13: 2673-83.
74. Tousoulis D, Paroutoglou IP, Papageorgiou N, Charakida M, Stefanadis C. Recent therapeutic approaches to platelet activation in coronary artery disease. Pharmacol Ther 2010; 127: 108-20.
75. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood 1997; 89: 1939-43.
76. Antoniades C, Tousoulis D, Vasiliadou C, Stefanadi E, Marinou K, Stefanadis C. Genetic polymorphisms of platelet glycoprotein Ia and the risk for premature myocardial infarction: effects on the release of sCD40L during the acute phase of premature myocardial infarction. J Am Coll Cardiol 2006; 47: 1959-66.
77. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with non-fatal myocardial infarction in younger patients. Blood 1999; 93: 2449-53.
78. Moshfegh K, Wuillemin WA, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999; 353: 351-4.
79. Casorelli I, De Stefano V, Leone AM, et al. The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. Br J Haematol 2001; 114: 150-4.
80. Zhao Y, Wang Y, Zhu J. Correlation between the polymorphism of glycoprotein Ia gene and acute coronary syndrome. Chin Med Sci J 2004; 19: 13-8.
81. Leone AM, De Stefano V, Burzotta F, et al. Glycoprotein Ia C807T gene polymorphism and increased risk of recurrent acute coronary syndromes: a five year follow up. Heart 2004; 90: 567-9.
82. Tsantes AE, Nikolopoulos GK, Bagos PG, Vaiopoulos G, Travlou A. Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and coronary artery disease: a meta-analysis. Int J Cardiol 2007; 118: 189-96.
83. Roest M, Banga JD, Grobbee DE, et al. Homozygosity for 807 T polymorphism in alpha(2) subunit of platelet alpha(2)beta(1) is associated with increased risk of cardiovascular mortality in high-risk women. Circulation 2000; 102: 1645-50.
84. Giusti B, Gori AM, Marcucci R, et al. Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis 2008; 196: 341-8.
85. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. 807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis 2004; 15: 427-33.
86. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol 2005; 96: 1095-9.
87. Bernardo E, Angiolillo DJ, Ramírez C, et al. Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. Platelets 2006; 17: 586-90.
88. Cuisset T, Frere C, Quilici J, et al. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. Thromb Haemost 2007; 97: 212-7.
89. Roth GJ. Developing relationships: arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. Blood 1991; 77: 5-19.
90. Du X. Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. Curr Opin Hematol 2007; 14: 262-9.
91. Clemetson KJ. A short history of platelet glycoprotein Ib complex. Thromb Haemost 2007; 98: 63-8.
92. Mikkelsson J, Perola M, Penttilä A, Karhunen PJ. Platelet glycoprotein Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation 2001; 104: 876-80.
93. Murata M, Matsubara Y, Kawano K, et al. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. Circulation 1997; 96: 3281-6.
94. Ozelo MC, Origa AF, Aranha FJ, et al. Platelet glycoprotein Ibalpha polymorphisms modulate the risk for myocardial infarction. Thromb Haemost 2004; 92: 384-6.
95. Candore G, Piazza G, Crivello A, et al. Association between platelet glycoprotein Ib-alpha and myocardial infarction: results of a pilot study performed in male and female patients from Sicily. Ann N Y Acad Sci 2006; 1089: 502-8.
96. Douglas H, Michaelides K, Gorog DA, et al. Platelet membrane glycoprotein Ibalpha gene-5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis. Heart 2002; 87: 70-4.
97. Kenny D, Muckian C, Fitzgerald DJ, Cannon CP, Shields DC. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. J Thromb Thrombolysis 2002; 13: 13-9.
98. Jin YY, Yu GZ, Wang Y, Cui LY, Xin XM. Variable number of tandem repeats polymorphism of platelet glycoprotein Ib alpha in Chinese people and CC genotype with aspirin sensitivity in patients with cerebral infarction. J Clin Pharm Ther 2009; 34: 239-43.
99. 12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-95.
100. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005; 45: 1157-64.
101. Rudez G, Bouman HJ, van Werkum JW, et al. Common variation in the platelet receptor P2RY12 gene is associated with residual onclopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet 2009; 2: 515-21.
102. 12 receptor are associated with coronary artery disease. BMC Med Genet 2007; 8: 59.
103. 12-ADP receptor gene. Int J Cardiol 2009; 133: 341-5.
104. 12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005; 16: 199-204.
105. 12-ADP receptor polymorphism on the efficacy of clopidogrel doseadjustment according to platelet reactivity monitoring in coronary artery disease patients. Thromb Res 2010; 125: e167-70.
106. 12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005; 116: 491-7.
107. Zee RY, Michaud SE, Diehl KA, et al. Purinergic receptor P2Y, Gprotein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism. Atherosclerosis 2008; 197: 694-9.
108. 12 antagonist cangrelor. Thromb Haemost 2010; 103: 379-86.
109. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006; 26: 1895-900.
110. 12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genom 2007; 17: 1057-64.
111. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735-41.
112. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429-36.
113. Kim KA, Park PW, Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol 2008; 64: 589-97.
114. Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008; 101: 1088-93.
115. Geisler T, Schaeffeler E, Dippon J, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008; 9: 1251-9.
116. Simon T, Verstuyft C, Mary-Krause M, et al.; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-75.
117. Lee JM, Park S, Shin DJ, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 2009; 104: 46-51.
118. Jinnai T, Horiuchi H, Makiyama T, et al. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ J 2009; 73: 1498-503.
119. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-34.
120. Gladding P, Webster M, Zeng I, et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008; 1: 620-7.
121. Gladding P, White H, Voss J, et al. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. JACC Cardiovasc Interv 2009; 2: 1095-101.
122. Pena A, Collet JP, Hulot JS, et al. Can we override clopidogrel resistance? Circulation 2009; 119: 2854-7.
123. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512-8.
124. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007; 119: 355-60.
125. Shanker J, Kakkar VV. Implications of genetic polymorphisms in inflammation-induced atherosclerosis. Open Cardiovasc Med J 2010; 4: 30-7.
126. Meisinger C, Prokisch H, Gieger C, et al. A genome-wide association study identifies three loci associated with mean platelet volume. Am J Hum Genet 2009; 84: 66-71.
127. Kunicki TJ, Nugent DJ. The genetics of normal platelet reactivity. Blood 2010; 116(15): 2627-34.
128. Wang C, Yan J, Yang P, Du R, Chen G. The relationship between CD40 gene polymorphism and unstable coronary atherosclerotic plaques. Clin Cardiol 2010; 33: E55-60.
129. Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping: one piece of the puzzle to personalize antiplatelet therapy. J Am Coll Cardiol 2010; 56: 112-6.